𝛼SK or Search

ENTITY

SciClone Pharmaceuticals (SCICLONE HK)

108

Analysis

Health Care • China

SciClone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing pharmaceutical products for oncology and severe infection in Mainland China and internationally. Its portfolio includes proprietary product Zadaxin, used for hepatitis B, hepatitis C, and certain cancers, as well as in-licensed products like Zometa, DANYELZA, and Angiomax. The company was founded in 1990 and is headquartered in Shanghai, China.

more

Refresh

Exchange Announcement • 27 Aug 2026 20:43

Interim Results Announcement For The Six Months Ended 30 June 2026

Exchange Announcement • 17 Aug 2026 16:34

Notice Of Board Meeting

Exchange Announcement • 05 Aug 2026 21:42

Voluntary Announcement Update On The Discloseable Transaction

Exchange Announcement • 01 Jul 2026 18:32

Voluntary Announcement Further Purchase Of H Shares Pursuant To The 2026 H Share Incentive Scheme And Cornerstone Investors' Confidence In The Group'S Long-Term Development

Exchange Announcement • 30 Jun 2026 20:01

Voluntary Announcement Voluntary Extension Of Lock-Up Undertaking Given By Chief Executive Officer

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x